Effect of Atorvastatin Versus Rosuvastatin on Levels of Serum Lipids, Inflammatory Markers and Adiponectin in Patients with Hypercholesterolemia

Abstract

Therapy with both statins not only significantly improved lipid profiles but also decreased levels of vascular biomarkers hs-CRP, MMP-9, and PAI-1; however, only rosuvastatin increased serum adiponectin levels significantly in patients with hypercholesterolemia, which could imply a beneficial effect in coronary artery disease.

Rosuvastatin and ellagic acid protect against isoproterenol-induced myocardial infarction in hyperlipidemic rats

“…Rosuvastatin, a lipid-lowering agent in clinical practice, has an appreciable anti-atherogenic property which is due to the improvement of endothelial dysfunction as well as its anti-thrombotic, anti-inflammatory and antioxidant effects (Qu et al, 2009;Rondi et al, 2014). Rosuvastatin has been reported to prevent MI induced experimentally by occlusion of left coronary artery in rats (Dourado et al, 2011).…”

Atorvastatin — 20 Years in the Struggle for Life

“…Снижение уровня вч-СРБ соста-вило 40% и 34%, соответственно, (р=0,139). Анало-гичные результаты были показаны в ряде других исследований [24][25][26]. Таким образом, в большинстве сравнительных исследований во влиянии на вч-СРБ аторвастатин не уступал розувастатину, несмотря на более выраженный гиполипидемический эффект последнего.…”

A meta-analysis of the effects of statins on serum C-reactive protein in Chinese population with coronary heart disease or hyperlipidemia

“…After being scanned, only eight studies were identified meeting the inclusion criteria and remained in the analyses [13][14][15][16][17][18][19][20] . Of the eight studies, four had routine-treatment groups [13][14][15][16] , which included no cholesterol-lowering drugs, two compared the effects of different doses of atorvastatin [17,18] , one compared the effect of atorvastatin versus rosuvastatin [19] , and one used healthy volunteers as a control group [20] . All eight articles could be used to evaluate the changes in serum levels of CRP and LDL-C from baseline to the end of follow-up, while only the four with routine-treatment groups could be used to compare the serum CRP and LDL-C levels after statin treatment with those after non-statin routine treatment [13][14][15][16] .…”

“…One study (12.5%) was from Hong Kong [17] , three (37.5%) from Taiwan [13,18,20] , and four (50%) from Mainland China [14][15][16]19] . Quality assessment, subject characteristics (such as the age, gender and clinical diagnosis), duration and dose of statin treatment of the included studies are shown in Table 1.…”